My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
July/August 2016
HCV Guidance Website Updated to Reflect Latest Drug Developments, a website developed by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) to provide up-to-date guidance on the treatment of hepatitis C (HCV) has updated several sections of the website based on newly available therapies and data.
The latest version of the HCV Guidance provides new recommendations regarding the optimal use of antiviral agents for hepatitis C in the wake of the approval by the Food and Drug Administration of sofosbuvir/velpatasvir. It also integrates recent trial data for other combinations of direct-acting antiviral agents, particularly in unique groups of patients, including those who have impaired kidney function, have undergone liver transplantation, or have HIV co-infection. 
“We believe that the updated recommendations will help caregivers with regimen choice not only in common treatment scenarios, but will also importantly provide guidance in cases where randomized trial data or specific FDA labeling may be lacking,” said Raymond Chung, MD, co-chair of the guidance panel. 
“The latest updates to bring a trusted document up to date with the latest therapeutic options. The guidance now offers more than one front-line regimen for each viral genotype and updates recommendations for patients of high complexity. Most treating clinicians will find workable treatment options for the majority of their patients,” said Hugo Vargas, MD, guidance panel co-chair. 
The update also offers guidance regarding the prudent use of HCV resistance testing, a source of considerable confusion for practitioners. Important information regarding the monitoring of patients with cirrhosis who are undergoing therapy with direct acting antivirals is also provided. Tables highlighting important potential drug-drug interactions between HCV antivirals and commonly prescribed medications, including antiretroviral and antirejection agents, have also been updated. 
“As more patients gain coverage for curative therapies, our panel hopes that the updated guidance allows more providers to join the fight against this deadly and expanding epidemic,” said Arthur Kim, MD, guidance panel co-chair. 
Visit for updates regarding the release of this and other sections of the guidance.

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:

Updated IDSA Guideline on Valley Fever Published in CID
Drug-Susceptible Tuberculosis Guidelines Now Available
Updated Guideline on Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia Now Available
HCV Guidance Website Updated to Reflect Latest Drug Developments
IDSA Partners with AGA on New Registry to Track Fecal Microbiota Transplants
CLSI Updates on Antimicrobial Susceptibility Testing Are Now Available
CDC Issues Travel Warning for Area in Miami Due to Locally Transmitted Zika Virus; Generic Version of Tamiflu Approved by FDA
Virtual Supervision of “Incident To” Services
Take 3 Minutes to Tell the UN to Take Global Action on Antimicrobial Resistance
As US Cases Mount, IDSA Continues To Push for Zika Funding
Massachusetts Passes Troubling Lyme Legislation
Party Platforms Include IDSA Priorities
Live from Durban: Science Speaks Covers AIDS 2016
Stipends Available to ID Medical Student Interest Groups
Vaccines Virtual Collection from CID
Upcoming Webinar on Antibiotic Drug Development
IDSA, HIVMA Seek Clinical Practice Guidelines Editor
IDSA Advocacy on ID-Led Stewardship—More Progress on our Strategic Priorities
Don’t Miss These IDSA Guidelines Updates
IDSA Honors 111 Distinguished Physicians, Scientists with FIDSA
IDWeek 2016: Not-to-Miss Sessions Featuring the Latest on the Zika Outbreak
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add '' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.